How COVID 19 Changed the Demand for Butterfly Needles
, by Andrew Odgers, 13 min reading time
Supply Chain
How COVID-19 Changed the Demand for Butterfly Needles and the Wider Medical Supply Chain
The COVID-19 pandemic disrupted medical supply chains on a scale not seen in living memory. Butterfly needles, along with virtually every other clinical consumable, were affected by sudden demand spikes, manufacturing constraints, and logistics failures. This guide explains what happened, why, what the lasting effects on procurement practice have been, and how UK clinical services can build more resilient supply arrangements going forward.
What happened
How the pandemic changed demand for phlebotomy consumables
The demand surge from COVID-19 blood testing
COVID-19 required enormous volumes of blood testing from the moment widespread clinical management began. Inflammatory markers, D-dimer, ferritin, lactate dehydrogenase, troponin, full blood count, coagulation profiles, and renal function panels became routine monitoring requirements for hospitalised COVID patients. Each patient required multiple daily collections in many cases, and the acuity and volume of patients requiring this monitoring was unprecedented in peacetime healthcare.
COVID patients as a clinical population also presented specific venepuncture challenges. Critically ill patients with prolonged hospital stays developed fragile, depleted vein access. Patients on anticoagulant therapy for COVID-related coagulopathy required careful collection technique. The combination of high collection volume and a patient population that disproportionately required butterfly needle collections drove demand for winged infusion sets to levels that existing supply chains were not designed to support.
The vaccination programme and additional demand
The mass COVID-19 vaccination programme from late 2020 onwards added a separate demand stream for needles, syringes, and related consumables that competed with clinical phlebotomy supply. Although vaccine administration uses different needle types, the manufacturing capacity for needle-based medical devices is shared across product categories, and the reallocation of manufacturing capacity towards vaccine delivery consumables created secondary pressure on the supply of butterfly needles and other clinical sharps products.
Pre-pandemic demand trends
Even before COVID-19, demand for butterfly needles had been increasing steadily for several years. The ageing UK population, growing preference among phlebotomists for butterfly needles in routine adult collections, expansion of community phlebotomy services, and broader adoption of safety-engineered sharps following the 2013 Regulations had all contributed to rising baseline demand. The pandemic hit a supply chain that was already under some pressure from secular demand growth.
Supply side
Why supply chains struggled to respond
Manufacturing concentration
Medical needle and sharps manufacturing is concentrated among a relatively small number of large global manufacturers, with significant production capacity located in Asia and, to a lesser extent, Europe. When COVID-19 disrupted manufacturing activity in major producing regions in early 2020, output from key facilities fell sharply at the same moment that demand was accelerating. The combination was severe for supply availability across all needle-based product categories.
The concentration of manufacturing also means that when one major producer has a quality event, a capacity issue, or a logistics problem, the effect ripples through multiple product lines and multiple markets simultaneously. This characteristic of the market, which was known before the pandemic, became acutely visible when several major producers faced simultaneous constraints in 2020 and 2021.
Logistics and shipping constraints
Global container shipping experienced severe disruption throughout 2020 and 2021. Container availability, port capacity, and air freight costs were all affected. Medical device supply chains that relied on regular shipping schedules from Asian manufacturing facilities experienced extended and unpredictable lead times. Products that had previously arrived in two to four weeks from order took eight to twelve weeks or longer, and even those extended lead times were not reliable.
For UK clinical services that had operated on lean just-in-time stock models, the logistics disruption exposed the fragility of relying on consistent short-lead-time delivery from distant manufacturers. Services that held larger stock buffers fared better than those that replenished frequently on the assumption of reliable next-week delivery.
Prioritisation and allocation
As shortages developed, both NHS Supply Chain and individual distributors moved to allocation models that limited the volume any single purchaser could acquire in a given period. This protected distribution equity across the NHS but created planning difficulties for services that needed to increase usage in response to clinical demand. Independent and private healthcare providers, community services, and GP surgeries were often at a disadvantage in this environment relative to acute NHS trusts.
What changed permanently
The lasting effects on procurement practice
Several procurement behaviours that were rare before the pandemic have become standard practice in well-managed clinical supply operations.
- Holding larger safety stock buffers. Services that were caught short in 2020 and 2021 subsequently increased their minimum stock holdings for critical consumables including butterfly needles. A safety stock equivalent to four to eight weeks of usage, rather than the one to two weeks common in lean pre-pandemic models, is now the target for many NHS procurement teams.
- Diversifying supplier relationships. Sole-supplier arrangements that had been preferred for administrative simplicity became a liability when that supplier was constrained. Services that had relationships with multiple qualified suppliers were able to source from alternative channels when primary suppliers were on allocation. Maintaining at least one alternative approved supplier for key consumables is now standard procurement guidance in most NHS supply strategies.
- Earlier ordering and longer forward planning cycles. Procurement cycles that had operated on monthly or even weekly replenishment moved towards quarterly planning with earlier order placement. The predictability of clinical consumable usage means that forward planning is achievable and that ordering earlier in the cycle is a low-risk way to build supply resilience.
- Greater attention to supply chain origin and manufacturing geography. Buyers who had not previously considered where their products were manufactured became acutely aware of this during the pandemic. Products with European or near-shore manufacturing footprints were generally more reliably available than those dependent on distant Asian production during periods of disruption. This has led to greater interest in the manufacturing geography of clinical consumables in procurement evaluation criteria.
- Investment in visibility and forecasting. Many larger NHS trusts and procurement networks invested in better supply chain visibility tools following the pandemic, enabling earlier warning of potential shortages and more rapid reallocation of available stock across sites. For butterfly needles specifically, improved demand forecasting based on patient mix data has allowed services to anticipate seasonal or patient acuity-related demand changes more accurately.
Reliable UK supply
Butterfly needles in stock with next-day UK delivery
Charles Medical holds consistent stock across all butterfly needle gauges and supplies next-day to UK clinical settings. Contact us to discuss standing order arrangements and volume pricing for your service.
For procurement specification and ordering questions, see our FAQ for Buyers: Everything You Wanted to Ask about Butterfly Needles.
Part of the hub
Back to the Butterfly Needle Knowledge Hub
This article is part of our complete butterfly needle knowledge base, covering clinical use, gauge selection, technique, haemolysis reduction, cost analysis, patient guidance, and the full regulatory picture for UK procurement.
Keep reading
Related guides in this hub
FAQ for Buyers: Everything You Wanted to Ask about Butterfly Needles covers ordering, stock management, and specification questions for procurement managers. Cost Analysis: Are Butterfly Needles Worth the Investment gives the full financial case for service-level procurement decisions. And What Are Butterfly Needles and How Do They Work covers the clinical fundamentals for those new to the product category.
Frequently asked
Supply chain and procurement questions answered
Is the butterfly needle supply chain back to normal after COVID-19?
Global medical device supply chains have largely stabilised since the peak disruption of 2020 to 2022. Lead times for butterfly needles from most major suppliers have returned to pre-pandemic ranges. However, the structural vulnerabilities that the pandemic exposed, particularly manufacturing concentration and dependence on long-haul logistics, remain. Most procurement professionals treat the post-pandemic supply environment as more stable but not as inherently resilient as it was assumed to be before 2020.
How much safety stock should a clinic hold for butterfly needles?
A minimum of four weeks of current usage is the widely adopted post-pandemic guidance for critical consumables including butterfly needles. Services with higher risk tolerance or less reliable alternative sourcing may target six to eight weeks. The appropriate level depends on your usage volume, your supplier relationships, your storage capacity, and your appetite for supply risk. Review and adjust your safety stock level periodically as your usage pattern changes.
Did COVID-19 affect butterfly needle quality as well as availability?
There were isolated reports of quality issues from some suppliers during the peak shortage period as manufacturers increased production rates and some purchasers sourced from less familiar suppliers. Services that sourced from established, MHRA-registered suppliers with known quality management systems generally did not experience quality deterioration. The lesson for procurement is that supply resilience and quality assurance are linked: sourcing from the cheapest available supplier in a shortage situation without verifying regulatory status carries quality risk.
Should I now hold multiple approved suppliers for butterfly needles?
Yes. Maintaining at least one alternative approved supplier for key consumables including butterfly needles is now considered good practice in NHS and independent healthcare procurement. The administrative work of qualifying an alternative supplier is modest compared to the operational risk of being unable to source a critical consumable when your primary supplier is constrained. A documented alternative supplier who has been evaluated and approved can be activated quickly when needed.